The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...
Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...
Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...
New treatments can slow the disease’s progress, which is why the Alzheimer’s Association is leveraging its celebrity partners ...
Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.
More specifically, Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35 percent, respectively. M Health Fairview and the University of ...
They are now facing the first direct competition to Leqembi from Eli Lilly's Kisunla (donanemab), which has been approved with a fixed duration of treatment until amyloid plaques in the brain resolve.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback